How to Determine Appropriate Washout Periods in BA/BE Crossover Trials

Introduction: The Significance of Washout in Crossover Studies

In bioavailability and bioequivalence (BA/BE) studies using a crossover design, the washout period plays a critical role in ensuring study integrity. The washout is the interval between two dosing periods during which the drug administered in the first period is expected to be sufficiently eliminated from the body before the second period begins. An inadequate washout can lead to carryover effects, jeopardizing the validity of pharmacokinetic (PK) comparisons and leading to regulatory rejection.

Regulatory agencies like the FDA, EMA, and CDSCO expect that the washout period be based on the pharmacokinetic properties of the drug, primarily the elimination half-life (t_1/2). This article explains how to determine the appropriate washout duration, addresses common pitfalls, and outlines regulatory expectations in crossover BE trials.

Understanding Elimination Half-Life and Its Role in Washout Calculation

The elimination half-life (t_1/2) of a drug is the time it takes for its plasma concentration to reduce by 50%. Washout duration is typically based on the time required to eliminate a significant proportion (≥97%) of the drug to ensure minimal residual presence at the time of next dosing.

Standard practice:

• Washout period = 5 to 7 × t_1/2
• At 5 half-lives, ~97% of drug is eliminated
• At 7 half-lives, ~99.2% elimination

Example: For a drug with t_1/2 = 8 hours, washout period should be ≥40 hours (5 × 8). For safety and regulatory compliance, 48–72 hours may be chosen to allow buffer time.

Pharmacokinetic Parameters to Consider

In addition to t_1/2, several other pharmacokinetic properties can influence washout duration:

• Absorption rate: Delayed-release or controlled-release formulations may extend drug presence
• Metabolite half-life: Some metabolites have longer half-lives than the parent compound
• Non-linear kinetics: Accumulation or saturation effects must be accounted for
• Route of elimination: Renal or biliary clearance rates may influence persistence

For drugs with enterohepatic recycling or lipophilic properties (e.g., amiodarone), even longer washout periods (10–15 half-lives) may be justified.

Regulatory Guidance on Washout Periods

Global agencies provide specific expectations regarding washout intervals:

• FDA: Recommends at least 5–7 t_1/2, adjusted based on metabolite and formulation behavior
• EMA: Emphasizes complete elimination of parent and active metabolites; washout must be justified in the protocol
• CDSCO: Follows similar standards, often requiring ≥7 t_1/2 and justification in protocol submissions

Protocols must clearly state the estimated t_1/2, supporting literature or pilot data, and rationale for chosen washout duration.

Real-World Example: Designing a Crossover Study for Loratadine

Loratadine has a t_1/2 of ~8 hours, but its active metabolite desloratadine has a t_1/2 of ~27 hours. Therefore, a washout of 7 × 27 = 189 hours (~8 days) is used to eliminate both parent and metabolite before Period 2.

Study Design:

• Design: Two-period, two-sequence, open-label crossover
• Subjects: 24 healthy volunteers
• Washout: 10-day interval between doses
• Rationale: Based on desloratadine’s half-life and regulatory precedence

Common Mistakes and Their Consequences

Incorrect washout duration can lead to regulatory and scientific issues:

• Carryover effect: Residual drug from the first period distorts Period 2 data
• Period bias: Statistical anomalies arise from incomplete elimination
• Regulatory rejection: Agencies may require repeat studies or deny approval
• Safety concerns: Risk of cumulative toxicity or interaction

To prevent these issues, investigators must ensure precise estimation of elimination kinetics and build adequate buffer time into washout schedules.

Measuring and Confirming Adequate Washout

Some protocols include pre-dose sampling in Period 2 to confirm drug absence. This serves as an additional quality control step and may include:

• Pre-dose blood sample: Collected immediately before second-period dosing
• Acceptance limit: Should be <5% of C_max from Period 1
• Result handling: If drug is detected, subject may be excluded from PK analysis

Regulatory agencies appreciate such precautionary measures as they reinforce data integrity and subject safety.

Operational Planning: Subject Scheduling and Compliance

Washout periods affect overall study timelines and subject retention. Longer washouts increase dropout risk and require efficient scheduling. Sponsors and CROs often use rolling recruitment, overlapping dosing groups, or rescheduling buffers to manage logistics.

GCP Tip: Provide clear washout instructions to subjects, including avoidance of drug-like substances, food restrictions, and alcohol abstinence to prevent contamination.

Conclusion: Washout Periods Safeguard Study Integrity

In BA/BE crossover trials, determining an adequate washout period is essential to ensuring scientific validity, regulatory compliance, and subject safety. This interval must be calculated based on thorough understanding of pharmacokinetics, particularly the elimination half-life of both the parent compound and active metabolites.

When in doubt, extend the washout or include pre-dose screening. A well-planned washout not only protects data integrity but also signals to regulators that your study design is rooted in rigorous scientific methodology.